MDMA — Pharmala Biotech Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- CA$10.86m
- CA$10.00m
- CA$0.61m
- 67
- 10
- 13
- 19
Annual cashflow statement for Pharmala Biotech Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.51 | -0.986 | -0.78 | -0.824 | -2.18 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.23 | 0.237 | 0.011 | 0.829 | 1.06 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.109 | 0.112 | 0.377 | -0.397 | -0.048 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.174 | -0.625 | -0.34 | -0.321 | -1.04 |
| Capital Expenditures | -0.262 | -0.995 | -0.507 | -0.226 | -0.035 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | 0.891 | 0 | — | — | -0.9 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.629 | -0.995 | -0.507 | -0.226 | -0.935 |
| Financing Cash Flow Items | — | — | — | 0.697 | 1.53 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 2.02 | 0 | 0.189 | 0.772 | 1.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.47 | -1.62 | -0.657 | 0.224 | -0.379 |